Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Parkinson's Disease

Free Subscription Articles published in Exp Neurol Retrieve available abstracts of 85 articles: HTML format

Single Articles

September 2026
1. WANG S, Cui Y, Zhang M, Zhao W, et al
   Progress in animal models of rapid eye movement sleep behavior disorder: Characteristics and applications.
   Exp Neurol. 2026;403:115823.
   PubMed     Abstract available
   
   
   May 2026
2. CALLEJA-CONDE J, Echeverry-Alzate V, Sanz-SanCristobal M, Alonso-Gil S, et al
   Therapeutic properties of ayahuasca component N,N-Dimethyltryptamine in a pre-clinical model of Parkinson's disease.
   Exp Neurol. 2026 May 12:115822. doi: 10.1016/j.expneurol.2026.115822.
   PubMed     Abstract available
   
   
   
3. DELONCLE R
   Conjecture for a free radical epimerization process in Alzheimer, Parkinson, Lewy body, amyotrophic lateral sclerosis, progressive Supranuclear Palsy and Creutzfeldt Jakob diseases.
   Exp Neurol. 2026 May 5:115812. doi: 10.1016/j.expneurol.2026.115812.
   PubMed     Abstract available
   
   
   April 2026
4. ZHANG S, An Y, Xu Y, Mi J, et al
   Transcranial magneto-acoustical stimulation regulates motor cortex-subthalamic nucleus neural activity to improve motor disorders in a Parkinson's disease mouse model.
   Exp Neurol. 2026 Apr 12:115763. doi: 10.1016/j.expneurol.2026.115763.
   PubMed     Abstract available
   
   
   
5. ALVAREZ-LUQUIN DD, Gonzalez-Fernandez RR, Ichikawa-Escamilla E, Torres-Velasco ME, et al
   Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets.
   Exp Neurol. 2026;402:115764.
   PubMed     Abstract available
   
   
   
6. SHEN Z, Garland B, Mellick GD, Ma L, et al
   A refined chronic MPTP/probenecid model of Parkinson's disease in mature adult mice.
   Exp Neurol. 2026 Apr 4:115759. doi: 10.1016/j.expneurol.2026.115759.
   PubMed     Abstract available
   
   
   March 2026
7. LIU T, Zhang M, Wei J
   Does ACE2 deficiency have a role in Parkinson's disease -exacerbated pulmonary fibrosis?
   Exp Neurol. 2026;401:115744.
   PubMed     Abstract available
   
   
   
8. ANAYYAT U, Mei X, Zhang F, Yi R, et al
   Neuroprotective effect of RMF in a mouse model of sporadic Parkinson's disease.
   Exp Neurol. 2026 Mar 18:115738. doi: 10.1016/j.expneurol.2026.115738.
   PubMed     Abstract available
   
   
   February 2026
9. KABAOGLU B, Garulli EL, De Sa R, Vogt A, et al
   Shift in motor-state equilibrium explains gait therapy effects of apomorphine in experimental Parkinsonism.
   Exp Neurol. 2026 Feb 27:115704. doi: 10.1016/j.expneurol.2026.115704.
   PubMed     Abstract available
   
   
   
10. QUAN Z, Ku CY, Xie T, Fok HT, et al
    Mitochondrial dysfunction and disrupted neuronal lipid homeostasis in Parkinson's disease: Potential mechanisms and therapeutic implications.
    Exp Neurol. 2026 Feb 25:115703. doi: 10.1016/j.expneurol.2026.115703.
    PubMed     Abstract available
    
    
    
11. DAS A, Das R, Das A, Aich P, et al
    Microbiome- metabolome signatures and Behavioral alterations in a progressive MPTP-induced mouse model of Parkinson's disease.
    Exp Neurol. 2026;400:115701.
    PubMed     Abstract available
    
    
    
12. ZHONG J, Xu J, Xue J, Qiu Z, et al
    Phosphodiesterase 4 as a therapeutic target in Parkinson's disease recent advances.
    Exp Neurol. 2026 Feb 9:115680. doi: 10.1016/j.expneurol.2026.115680.
    PubMed     Abstract available
    
    
    January 2026
13. WANG L, Wang Y, Yang S, Bai Y, et al
    Long-term continuous theta burst stimulation ameliorates L-DOPA-induced dyskinesia in Parkinsonian rats through modulation of the cerebello-thalamo-striatal circuit.
    Exp Neurol. 2026;399:115674.
    PubMed     Abstract available
    
    
    
14. HAJIBABAEI M, Jafarvand B, Beirami E, Valian N, et al
    Imipramine improves motor impairments in a rat model of Parkinson's disease induced by 6-hydroxydopamine; the role of oxidative stress and neurotrophic factors.
    Exp Neurol. 2026 Jan 13:115646. doi: 10.1016/j.expneurol.2026.115646.
    PubMed     Abstract available
    
    
    
15. TIAN S, Niu M, Qian Q, Zhang K, et al
    Biochanin A exerts neuroprotective effects in Parkinson's disease both in vivo and in vitro by improving mitochondrial dysfunction through the Sirt1 signaling pathway.
    Exp Neurol. 2026;398:115636.
    PubMed     Abstract available
    
    
    December 2025
16. KILPELAINEN T, Yang R, Toivio J, Etelainen T, et al
    Novel PREP ligand, HUP-46, ameliorates behavioral deficits in an alpha-synuclein based Parkinson's disease model.
    Exp Neurol. 2025 Dec 10:115593. doi: 10.1016/j.expneurol.2025.115593.
    PubMed     Abstract available
    
    
    
17. LIU R, Wang R, Zhou X, Chu F, et al
    Noninvasive deep brain stimulation using theta-burst transcranial magnetic-acoustic coupling to modulate cortical rhythms in Parkinsonian mice.
    Exp Neurol. 2025;397:115592.
    PubMed     Abstract available
    
    
    November 2025
18. SABOURIN S, Modi K, Williams J, Singh R, et al
    Levodopa differentially modulates spectral features in cerebellum and basal ganglia in a rodent model of Parkinson's disease.
    Exp Neurol. 2025;397:115579.
    PubMed     Abstract available
    
    
    
19. RUIZ MCM, Goulart JT, Dos Santos Penha G, de Santana IA, et al
    Early deep brain stimulation attenuates parkinsonism progression in a neurotoxin-induced Parkinson's disease mouse model.
    Exp Neurol. 2025 Nov 22:115567. doi: 10.1016/j.expneurol.2025.115567.
    PubMed     Abstract available
    
    
    
20. ELGHAREEB MM, Elshopakey GE, Rezk S, Ateya A, et al
    Platelet-rich plasma intervention as a therapeutic agent versus L-DOPA in Parkinson's model induced by rotenone in male albino rats.
    Exp Neurol. 2025 Nov 8:115545. doi: 10.1016/j.expneurol.2025.115545.
    PubMed     Abstract available
    
    
    October 2025
21. NAIDJI C, Katrib C, Devos D, Durieux N, et al
    Histo-radiological correlations in an early-stage model of a Parkinson's disease.
    Exp Neurol. 2025 Oct 29:115538. doi: 10.1016/j.expneurol.2025.115538.
    PubMed     Abstract available
    
    
    
22. SUN W, Wei J, Lin Z, Jiang C, et al
    An involvement of ribonuclease L in Parkinson's disease via modulating the Th17/Treg balance by microRNA-7.
    Exp Neurol. 2025;396:115517.
    PubMed     Abstract available
    
    
    
23. ISHII A, Meredith JR, Corenblum MJ, Bernard K, et al
    Lasmiditan ameliorates cortico-hippocampal pathology and improves cognition in aging parkinsonian mice.
    Exp Neurol. 2025 Oct 12:115502. doi: 10.1016/j.expneurol.2025.115502.
    PubMed     Abstract available
    
    
    
24. XU N, Du C, Yu Y, Li Y, et al
    Corrigendum to "Urolithin A improves Parkinson's disease-associated cognitive impairment through modulation of neuroinflammation and neuroplasticity" [Experiment neurology, 2025 Nov:393:115395, Manuscript ID during submission is EXNR-25-789, The proof
    Exp Neurol. 2025 Oct 10:115484. doi: 10.1016/j.expneurol.2025.115484.
    PubMed    
    
    
    
25. VENKATESH S, Kinzonzi N, Galfano A, Shah A, et al
    Optimizing L-DOPA treatment through treadmill controlled exercise in a hemi-parkinsonian rat model.
    Exp Neurol. 2025 Oct 8:115497. doi: 10.1016/j.expneurol.2025.115497.
    PubMed     Abstract available
    
    
    
26. MOLLER M, Nieweler JA, Nikulin VV, van Riesen C, et al
    Network mechanisms in rapid-onset dystonia-parkinsonism.
    Exp Neurol. 2025;395:115491.
    PubMed     Abstract available
    
    
    September 2025
27. BERTASINI C, Rossini M, Grisotto J, Emerich D, et al
    Gene therapy device-based delivery of progranulin, prosaposin, and GDNF as a combined precision and neurorestorative therapy in the rat 6-OHDA model of parkinsonism.
    Exp Neurol. 2025;395:115474.
    PubMed     Abstract available
    
    
    August 2025
28. WU X, Hui Y, Wang L, Qiao H, et al
    Long-term intermittent theta burst stimulation alleviates Parkinson's disease-related cognitive impairment by modulating GluN2B in the dorsal hippocampus.
    Exp Neurol. 2025;394:115439.
    PubMed     Abstract available
    
    
    
29. MIN X, Du Z, Wei J, Yuan Z, et al
    Corrigendum to "Pyridoxal Phosphate inhibits alpha-synuclein-induced ferroptosis by activating GOT1 to enhance the methionine salvage pathway in Parkinson's Disease" [Experimental Neurology (2025) 115411].
    Exp Neurol. 2025 Aug 20:115429. doi: 10.1016/j.expneurol.2025.115429.
    PubMed    
    
    
    
30. LU X, Qi Y, Xue J, Tang X, et al
    Chemogenetic activation of VTA neurons induces anxiety-like behavior in a Parkinson's disease model.
    Exp Neurol. 2025 Aug 12:115425. doi: 10.1016/j.expneurol.2025.115425.
    PubMed     Abstract available
    
    
    
31. MIN X, Du Z, Wei J, Yuan Z, et al
    Pyridoxal phosphate inhibits alpha-synuclein-induced ferroptosis by activating GOT1 to enhance the methionine salvage pathway in Parkinson's disease.
    Exp Neurol. 2025;393:115411.
    PubMed     Abstract available
    
    
    July 2025
32. XU N, Du C, Yu Y, Li Y, et al
    Urolithin a improves Parkinson's disease-associated cognitive impairment through modulation of neuroinflammation and neuroplasticity.
    Exp Neurol. 2025 Jul 24:115395. doi: 10.1016/j.expneurol.2025.115395.
    PubMed     Abstract available
    
    
    
33. LIU Y, Wang R, Sun F, Wang N, et al
    Stereotactic infusion of rotenone into the SN induced a late-stage model of Parkinson's disease.
    Exp Neurol. 2025 Jul 20:115382. doi: 10.1016/j.expneurol.2025.115382.
    PubMed     Abstract available
    
    
    
34. SINGH AA, Pathak Z, Chawathe A, Chopra M, et al
    High fat diet and low dose-rotenone exposure exacerbate Parkinson's disease like pathology through gut-brain axis disruption.
    Exp Neurol. 2025 Jul 19:115384. doi: 10.1016/j.expneurol.2025.115384.
    PubMed     Abstract available
    
    
    
35. MORISE S, Tohge R, Oki M, Takenouchi N, et al
    Zonisamide modulates cholinergic markers and alleviates levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Exp Neurol. 2025;393:115383.
    PubMed     Abstract available
    
    
    June 2025
36. KOC HI, Dogan E, Yelkenci HE, Bayraktaroglu C, et al
    Circadian rhythm disruption exacerbates neurodegeneration and alters proteomic profiles in a 6-OHDA induced Parkinson's disease model.
    Exp Neurol. 2025 Jun 23:115356. doi: 10.1016/j.expneurol.2025.115356.
    PubMed     Abstract available
    
    
    
37. XU Y, Zhang S, Mi J, Lu X, et al
    Modulatory effects of transcranial magneto-acoustic stimulation on behavior and corticostriatal transmission of oscillatory activity in a mouse model of Parkinson's disease induced by MPTP.
    Exp Neurol. 2025;392:115352.
    PubMed     Abstract available
    
    
    May 2025
38. ZIKEREYA T, Liu C, Wei L, Wang Y, et al
    The cannabinoid receptor 1 mediates exercise-induced improvements of motor skill learning and performance in parkinsonian mouse.
    Exp Neurol. 2025 May 6:115289. doi: 10.1016/j.expneurol.2025.115289.
    PubMed     Abstract available
    
    
    
39. PENG Y, Jiang DY, Yao SY, Zhang X, et al
    Gene-modified animal models of Parkinson's disease.
    Exp Neurol. 2025;390:115287.
    PubMed     Abstract available
    
    
    
40. MA J, Yang Y, Zang C, Chen Q, et al
    Inhibiting mitochondrial excessive fission alleviates the neuronal damage in Parkinson's disease via regulating PGC-1alpha mediated mitochondrial biogenesis.
    Exp Neurol. 2025 May 2:115288. doi: 10.1016/j.expneurol.2025.115288.
    PubMed     Abstract available
    
    
    April 2025
41. HONG JY, Lee JS, Kim SH, Lee PH, et al
    A model of L-DOPA-induced dyskinesia in parkinsonian mice produced by AAV vector-mediated overexpression of alpha-synuclein.
    Exp Neurol. 2025;389:115264.
    PubMed     Abstract available
    
    
    
42. ZHANG Y, Liang C, Weng M, Zhang Z, et al
    Intestinal alterations of mucosal barrier integrity, motility and enteric nerve in cynomolgus monkey model of Parkinson's disease.
    Exp Neurol. 2025;389:115256.
    PubMed     Abstract available
    
    
    
43. FENG N, Huang X, Jia Y
    Small extracellular vesicles from adipose derived stem cells alleviate microglia activation and improve motor deficit of Parkinson's disease via mir-100-5p/DTX3L/STAT1 signal axis.
    Exp Neurol. 2025 Apr 5:115250. doi: 10.1016/j.expneurol.2025.115250.
    PubMed     Abstract available
    
    
    
44. ZHANG L, Yan J, Song S, Yang Y, et al
    Detection of anxiety and depression-like behavior and intra-brain pathological markers in Parkinsonian cynomolgus monkeys.
    Exp Neurol. 2025;389:115242.
    PubMed     Abstract available
    
    
    March 2025
45. GAO Y, Liu W, Shi L, Yang P, et al
    Narirutin reduces microglia-mediated neuroinflammation by inhibiting the JAK2/STAT3 pathway in MPP(+)/MPTP-induced Parkinson's disease models.
    Exp Neurol. 2025;389:115232.
    PubMed     Abstract available
    
    
    February 2025
46. MIRANDA NC, Aquino YC, Macedo TO, Oliveira LM, et al
    Role of substantia Nigra dopaminergic neurons in respiratory modulation and limitations of levodopa in Parkinson's disease.
    Exp Neurol. 2025;387:115193.
    PubMed     Abstract available
    
    
    January 2025
47. LIANG JY, Yuan XL, Jiang JM, Zhang P, et al
    Targeting the NLRP3 inflammasome in Parkinson's disease: From molecular mechanism to therapeutic strategy.
    Exp Neurol. 2025 Jan 28:115167. doi: 10.1016/j.expneurol.2025.115167.
    PubMed     Abstract available
    
    
    
48. LIU T, Wu H, Wei J
    Molecular insights into Parkinson's disease and type 2 diabetes mellitus: Metformin's role and genetic pathways explored.
    Exp Neurol. 2025;385:115137.
    PubMed     Abstract available
    
    
    
49. QIAO CM, Ma XY, Tan LL, Xia YM, et al
    Indoleamine 2, 3-dioxygenase 1 inhibition mediates the therapeutic effects in Parkinson's disease mice by modulating inflammation and neurogenesis in a gut microbiota dependent manner.
    Exp Neurol. 2025 Jan 8:115142. doi: 10.1016/j.expneurol.2025.115142.
    PubMed     Abstract available
    
    
    December 2024
50. MONNOT C, Kalomoiri M, MacNicol E, Kim E, et al
    Early alterations of functional connectivity, regional brain volumes and astrocyte markers in the beta-sitosterol beta-d-glucoside (BSSG) rat model of parkinsonism.
    Exp Neurol. 2024 Dec 21:115118. doi: 10.1016/j.expneurol.2024.115118.
    PubMed     Abstract available
    
    
    
51. HUANG XL, Hu Y, Jiang W, Jiang JM, et al
    Suppression of cGAS/STING pathway-triggered necroptosis in the hippocampus relates H(2)S to attenuate cognitive dysfunction of Parkinson's disease.
    Exp Neurol. 2024 Dec 3:115093. doi: 10.1016/j.expneurol.2024.115093.
    PubMed     Abstract available
    
    
    
52. WANG H, Wu S, Jiang X, Li W, et al
    Acteoside alleviates salsolinol-induced Parkinson's disease by inhibiting ferroptosis via activating Nrf2/SLC7A11/GPX4 pathway.
    Exp Neurol. 2024 Dec 2:115084. doi: 10.1016/j.expneurol.2024.115084.
    PubMed     Abstract available
    
    
    
53. DAADI MM, Snyder EY
    Exercise your graft - An important lesson for cell replacement therapy for Parkinson's disease.
    Exp Neurol. 2024 Dec 2:115085. doi: 10.1016/j.expneurol.2024.115085.
    PubMed     Abstract available
    
    
    November 2024
54. NAKAMURA K
    Editorial: Intersection of neural activity, synuclein and Parkinson's disease.
    Exp Neurol. 2024 Nov 30:115091. doi: 10.1016/j.expneurol.2024.115091.
    PubMed    
    
    
    
55. SERRA M, Faustini G, Brembati V, Casu MA, et al
    Early alpha-synuclein/synapsin III co-accumulation, nigrostriatal dopaminergic synaptopathy and denervation in the MPTPp mouse model of Parkinson's Disease.
    Exp Neurol. 2024 Nov 3:115040. doi: 10.1016/j.expneurol.2024.115040.
    PubMed     Abstract available
    
    
    October 2024
56. LI Z, Luo J, Li C, Zhu H, et al
    Upregulation of Nav1.6 expression in the ventral posterolateral nucleus of thalamus contributes to hyperalgesia in a model of Parkinson's disease.
    Exp Neurol. 2024 Oct 25:115032. doi: 10.1016/j.expneurol.2024.115032.
    PubMed     Abstract available
    
    
    
57. ZHONG J, Yu X, Zhong Y, Tan L, et al
    GSK-3beta inhibitor amplifies autophagy-lysosomal pathways by regulating TFEB in Parkinson's disease models.
    Exp Neurol. 2024 Oct 25:115033. doi: 10.1016/j.expneurol.2024.115033.
    PubMed     Abstract available
    
    
    
58. SHI Y, Zhang J, Xiu M, Xie R, et al
    The zona incerta system: Involvement in Parkinson's disease.
    Exp Neurol. 2024 Oct 9:114992. doi: 10.1016/j.expneurol.2024.114992.
    PubMed     Abstract available
    
    
    September 2024
59. PAREKH P, Serra M, Allaw M, Perra M, et al
    Extract from Nasco pomace loaded in nutriosomes exerts anti-inflammatory effects in the MPTP mouse model of Parkinson's disease.
    Exp Neurol. 2024 Sep 18:114958. doi: 10.1016/j.expneurol.2024.114958.
    PubMed     Abstract available
    
    
    August 2024
60. BERNARD K, Mota JA, Wene P, Corenblum MJ, et al
    The angiotensin (1-7) glycopeptide PNA5 improvescognition in achronic progressive mouse model of Parkinson's disease through modulation of neuroinflammation.
    Exp Neurol. 2024 Aug 15:114926. doi: 10.1016/j.expneurol.2024.114926.
    PubMed     Abstract available
    
    
    
61. NACCARATO MC, Oliveira LM, Ferreira CB, Moreira TS, et al
    Nucleus of the solitary tract neuronal degeneration and impaired hypoxia response in a model of Parkinson's disease.
    Exp Neurol. 2024 Aug 13:114924. doi: 10.1016/j.expneurol.2024.114924.
    PubMed     Abstract available
    
    
    July 2024
62. SAGREDO GT, Tanglay O, Shahdadpuri S, Fu Y, et al
    ?-Synuclein levels in Parkinson's disease - Cell types and forms that contribute to pathogenesis.
    Exp Neurol. 2024;379:114887.
    PubMed     Abstract available
    
    
    June 2024
63. KASANGA EA, Soto I, Centner A, McManus R, et al
    Moderate intensity aerobic exercise alleviates motor deficits in 6-OHDA lesioned rats and reduces serum levels of biomarkers of Parkinson's disease severity without recovery of striatal dopamine or tyrosine hydroxylase.
    Exp Neurol. 2024;379:114875.
    PubMed     Abstract available
    
    
    
64. LEI J, Tang LL, Jing R, You HJ, et al
    Antinociceptive role of the thalamic dopamine D3 receptor in descending modulation of intramuscular formalin-induced muscle nociception in a rat model of Parkinson's disease.
    Exp Neurol. 2024 Jun 13:114846. doi: 10.1016/j.expneurol.2024.114846.
    PubMed     Abstract available
    
    
    April 2024
65. FERREIRA AFF, Ulrich H, Feng ZP, Sun HS, et al
    Neurodegeneration and glial morphological changes are both prevented by TRPM2 inhibition during the progression of a Parkinson's disease mouse model.
    Exp Neurol. 2024;377:114780.
    PubMed     Abstract available
    
    
    March 2024
66. RUNWAL GM, Edwards RH
    The role of alpha-synuclein in exocytosis.
    Exp Neurol. 2024;373:114668.
    PubMed     Abstract available
    
    
    February 2024
67. JACQUES WJ, Estelle M, Samuel G, Belkacem M, et al
    State-dependent alteration of respiration in a rat model of Parkinson's disease.
    Exp Neurol. 2024 Feb 21:114740. doi: 10.1016/j.expneurol.2024.114740.
    PubMed     Abstract available
    
    
    
68. FU X, Qu L, Xu H, Xie J, et al
    Ndfip1 protected dopaminergic neurons via regulating mitochondrial function and ferroptosis in Parkinson's disease.
    Exp Neurol. 2024;375:114724.
    PubMed     Abstract available
    
    
    January 2024
69. MAZZOCCO MT, Serra M, Maspero M, Coliva A, et al
    Positive relation between dopamine neuron degeneration and metabolic connectivity disruption in the MPTP plus probenecid mouse model of Parkinson's disease.
    Exp Neurol. 2024 Jan 26:114704. doi: 10.1016/j.expneurol.2024.114704.
    PubMed     Abstract available
    
    
    
70. DAADI EW, Daadi ES, Oh T, Li M, et al
    Combining physical & cognitive training with iPSC-derived dopaminergic neuron transplantation promotes graft integration & better functional outcome in parkinsonian marmosets.
    Exp Neurol. 2024 Jan 23:114694. doi: 10.1016/j.expneurol.2024.114694.
    PubMed     Abstract available
    
    
    
71. SEILER JL, Zhuang X, Nelson AB, Lerner TN, et al
    Dopamine across timescales and cell types: Relevance for phenotypes in Parkinson's disease progression.
    Exp Neurol. 2024;374:114693.
    PubMed     Abstract available
    
    
    
72. ESER P, Kocabicak E, Bekar A, Temel Y, et al
    Insights into neuroinflammatory mechanisms of deep brain stimulation in Parkinson's disease.
    Exp Neurol. 2024 Jan 8:114684. doi: 10.1016/j.expneurol.2024.114684.
    PubMed     Abstract available
    
    
    December 2023
73. CORSI S, Scheggi S, Pardu A, Braccagni G, et al
    Corrigendum to "Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease" [Experimental neurology 2023 May;363:114370].
    Exp Neurol. 2023 Dec 15:114640. doi: 10.1016/j.expneurol.2023.114640.
    PubMed    
    
    
    
74. MANCHINU MF, Pala M, Palmas MF, Diana MA, et al
    Region-specific changes in gene expression are associated with cognitive deficits in the alpha-synuclein-induced model of Parkinson's disease: A transcriptomic profiling study.
    Exp Neurol. 2023 Dec 11:114651. doi: 10.1016/j.expneurol.2023.114651.
    PubMed     Abstract available
    
    
    
75. RADEMACHER K, Nakamura K
    Role of dopamine neuron activity in Parkinson's disease pathophysiology.
    Exp Neurol. 2023 Dec 11:114645. doi: 10.1016/j.expneurol.2023.114645.
    PubMed     Abstract available
    
    
    
76. ESER P, Kocabicak E, Bekar A, Temel Y, et al
    The interplay between neuroinflammatory pathways and Parkinson's disease.
    Exp Neurol. 2023 Dec 5:114644. doi: 10.1016/j.expneurol.2023.114644.
    PubMed     Abstract available
    
    
    
77. NIU B, Zhao M, Gao X, Xu J, et al
    TMT-based quantitative proteomics analysis of neuroprotective effects of Forsythoside A on the MPTP-induced Parkinson's disease mouse model.
    Exp Neurol. 2023 Dec 4:114642. doi: 10.1016/j.expneurol.2023.114642.
    PubMed     Abstract available
    
    
    November 2023
78. XIAO Z, Wang X, Pan X, Xie J, et al
    Mitochondrial iron dyshomeostasis and its potential as a therapeutic target for Parkinson's disease.
    Exp Neurol. 2023;372:114614.
    PubMed     Abstract available
    
    
    October 2023
79. BARCOMB K, Ford CP
    Alterations in neurotransmitter co-release in Parkinson's disease.
    Exp Neurol. 2023;370:114562.
    PubMed     Abstract available
    
    
    August 2023
80. KASANGA EA, Han Y, Shifflet MK, Navarrete W, et al
    Nigral-specific increase in ser31 phosphorylation compensates for tyrosine hydroxylase protein and nigrostriatal neuron loss: Implications for delaying parkinsonian signs.
    Exp Neurol. 2023;368:114509.
    PubMed     Abstract available
    
    
    
81. KASANGA EA, Han Y, Navarrete W, McManus R, et al
    Differential expression of RET and GDNF family receptor, GFR-alpha1, between striatum and substantia nigra following nigrostriatal lesion: A case for diminished GDNF-signaling.
    Exp Neurol. 2023;366:114435.
    PubMed     Abstract available
    
    
    June 2023
82. LIU Y, Liu H, Lu Y, Yin X, et al
    Non-invasive auditory and visual stimulation attenuates alpha-Synuclein deposition and improves motor and non-motor symptoms in PD mice.
    Exp Neurol. 2023;364:114396.
    PubMed     Abstract available
    
    
    May 2023
83. HART M, Conrad J, Barrett E, Legg K, et al
    X-linked hydrocephalus genes: Their proximity to telomeres and high a + T content compared to Parkinson's disease.
    Exp Neurol. 2023 May 6:114433. doi: 10.1016/j.expneurol.2023.114433.
    PubMed     Abstract available
    
    
    April 2023
84. RIVAS-SANTISTEBAN R, Lillo J, Raich I, Munoz A, et al
    The cannabinoid CB(1) receptor interacts with the angiotensin AT(2) receptor. Overexpression of AT(2)-CB(1) receptor heteromers in the striatum of 6-hydroxydopamine hemilesioned rats.
    Exp Neurol. 2023;362:114319.
    PubMed     Abstract available
    
    
    March 2023
85. SARA C, Simona S, Alessandra P, Giulia B, et al
    Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
    Exp Neurol. 2023 Mar 4:114370. doi: 10.1016/j.expneurol.2023.114370.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Parkinson's Disease is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum